目的 探討甘海胃康膠囊聯(lián)合艾司奧美拉唑鈉治療反流性食管炎的臨床效果。方法 選取2021年3月—2022年12月安陽市人民醫(yī)院收治的122例反流性食管炎患者，按照隨機數(shù)字表法分為對照組和治療組，每組各61例。對照組靜脈滴注注射用艾司奧美拉唑鈉，每次將40 mg溶于100 mL的0.9%氯化鈉注射液中，20～30 min/次，2次/d。治療組在對照組治療基礎(chǔ)上口服甘海胃康膠囊，6粒/次，3次/d。兩組療程均為7 d。觀察兩組的臨床療效，比較兩組治療前后典型癥狀評分、漢密爾頓焦慮量表（HAMA）、17項漢密爾頓抑郁量表（HAMD-17）評分、胃食管反流病問卷（GerdQ）評分、內(nèi)鏡積分、食管24 h pH-阻抗監(jiān)測參數(shù)變化。結(jié)果 治療后，治療組總有效率是96.72%，顯著高于對照組的86.89%（P＜0.05）。治療后，兩組反酸、燒心、胸骨后痛評分均較治療前顯著下降（P＜0.05）；治療后，治療組典型癥狀評分顯著低于對照組（P＜0.05）。治療后，兩組HAMA、HAMD-17、GerdQ評分和內(nèi)鏡積分均顯著降低（P＜0.05）；治療后，治療組HAMA、HAMD-17、GerdQ評分和內(nèi)鏡積分均低于對照組（P＜0.05）。治療后，兩組反流總次數(shù)、最長反流時間及立位酸反流、液體反流和混合反流的次數(shù)均顯著減少（P＜0.05）；且均以治療組改善更顯著（P＜0.05）。結(jié)論 甘海胃康膠囊聯(lián)合艾司奧美拉唑鈉治療反流性食管炎具有較好的臨床療效，可明顯改善臨床癥狀與食管黏膜狀態(tài)，同時可大幅提升精神心理狀況及生活質(zhì)量，值得臨床推廣應(yīng)用。

Objective To explore the clinical effect of Ganhai Weikang Capsules combined with esomeprazole sodium in treatment of reflux esophagitis. Methods A total of 122 patients with reflux esophagitis treated in Anyang People’s Hospital from March 2021 to December 2022 were selected and divided into control group and treatment group according to random number table method, with 61 cases in each group. Patients in control group were iv administered with Esomeprazole Sodium for injection, 40 mg of this product was dissolved in 100 mL 0.9% sodium chloride injection, 20 — 30 min/time, twice daily. Patients in the treatment group were po administered with Ganhai Weikang Capsules on the basis of the control group, 6 grains/time, three times daily. The treatment course of both groups was 7 d. The clinical efficacy of two groups was observed. The changes of typical symptom scores, Hamilton Anxiety Scale (HAMA), 17 Hamilton Depression Scale (HAMD-17) scores, GerdQ scores, endoscopic scores, and esophageal 24-hour pH impedance monitoring parameters before and after treatment were compared between two groups. Results After treatment, the total effective rate of treatment group was 96.72%, significantly higher than that of control group (86.89%) (P < 0.05). After treatment, the scores of acid reflux, heartburn, and retrosternal pain in two groups were significantly decreased compared with those before treatment (P < 0.05). After treatment, the typical symptom score of treatment group was significantly lower than that of control group (P < 0.05). After treatment, HAMA, HAMD-17, GerdQ scores, and endoscopic scores were significantly decreased in both groups (P < 0.05). After treatment, HAMA, HAMD-17, GerdQ scores, and endoscopic scores in treatment group were lower than those in control group ( P < 0.05). After treatment, the total number of reflux, the longest reflux time and the number of orthostatic acid reflux, liquid reflux and mixed reflux were significantly reduced in both groups (P < 0.05). The improvement was more significant in treatment group (P < 0.05). Conclusion Ganhai Weikang Capsules combined with esomeprazole sodium has good clinical efficacy in treatment of reflux esophagitis, and can significantly improve clinical symptoms and esophageal mucosa status, and significantly improve mental and psychological status and life quality, which is worthy of clinical application.

R975

安陽市科技計劃項目（2021C01SF045）